SGLT2i (or GLP1RA) are still the likely preferred second-line agents when escalation of metformin therapy is required (including those aged 10-17 years)—patients without cardiovascular or renal disease who are overweight or obese

People with type 2 diabetes requiring escalation from metformin, including those aged 10–17 years and those who are overweight or obese without cardiovascular or kidney disease

Use an SGLT2 inhibitor or GLP-1 receptor agonist as the preferred second-line agent

Other second-line glucose-lowering agents

Glycemic control and weight management